Image 1 of 1
The Food and Drug Administration has not evaluated these statements. This product is not designed to diagnose, treat, cure, or prevent any medical condition. Not intended for human consumption.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic growth hormone–releasing hormone (GHRH) analog composed of a 30–amino acid sequence that has been engineered for increased structural stability and prolonged activity relative to native GHRH fragments. The distinguishing feature of this variant is the DAC modification, which enables binding to plasma proteins—such as albumin—resulting in an extended circulating half-life.
This prolonged duration makes CJC-1295 with DAC a useful tool in studies examining sustained peptide activity, pharmacokinetic behavior, and receptor-interaction dynamics. Research models investigate its influence on growth hormone–release pathways and the extent to which DAC modification affects systemic distribution and clearance when compared to non-DAC analogs.
CJC-1295 with DAC is intended exclusively for controlled laboratory research, providing a platform for studying peptide engineering, extended-release strategies, and protein-binding mechanisms.